Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 68Ga-DOTA-NI-FAPI04 |
Target |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carcinoma | Phase 1 | CN | 01 Apr 2024 | |
Fibrosis, Liver | Phase 1 | CN | 01 Sep 2020 | |
Breast Cancer | Preclinical | DE | 06 Apr 2018 |
Not Applicable | - | 68Ga-FAPI-04 PET/CT | uwldkhoxyu(iigrefkeww) = bkmppkskkr dkhmvojqan (mfmouizpsz ) | - | 08 Aug 2022 | ||
(18F-FDG PET/CT) | uwldkhoxyu(iigrefkeww) = wjkuqvjrfx dkhmvojqan (mfmouizpsz ) | ||||||
Not Applicable | Interstitial lung disease due to systemic disease Fibroblast Activation Protein (FAP) | 21 | (SSc-ILD patients) | ihnrrthfbj(fvlfxxyvrk) = eaewvfmcsw nvaxutzyse (fsywgxmbvv ) View more | - | 02 Jun 2021 |